The Implications of New Research Findings for the Management of Endometrial Cancer
Oncology Today with Dr Neil Love
00:00
Ruby and GY018: A Comparison of DMMR and COVID
Ruby is a phase three randomized trial chemotherapy, plus minus distarlamab. This maintenance went on for up to three years. The trend was actually worse receiving checkpoint in the PMMR population. So this really had us a nervous about what are we going to see in the Ruby trial and in GY018.
Transcript
Play full episode
